Name and surname:
|
doc. MUDr. Mária Bucová, CSc.
|
Document type:
|
Research/art/teacher profile of a person
|
The name of the university:
|
Comenius University Bratislava
|
The seat of the university:
|
Šafárikovo námestie 6, 818 06 Bratislava
|
III.a - Occupation-position | III.b - Institution | III.c - Duration |
---|---|---|
internal aspirant (internal doctoral student) | Department of Medical Microbiology and Immunology, Faculty of Medicine, Comenius University, Bratislava | 1983-1987 |
assistent | Department of Medical Microbiology and Immunology, Faculty of Medicine, Comenius University, Bratislava | 1988-1988 |
assistant professor | Department of Medical Microbiology and Immunology, Faculty of Medicine, Comenius University, Bratislava | 1988-1992 |
assistant professor | Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava | 1992-2008 |
Associated professor | Institute of immunology, Faculty of Medicine, Comenius University, Bratislava | 2008- up to now |
V.1.a - Name of the profile course | V.1.b - Study programme | V.1.c - Degree | V.1.d - Field of study |
---|---|---|---|
Immunology | General Medicine | II | General Medicine |
Dentistry | Immunology | II | Dentistry |
New Trends in Medical Microbiology and Immunology | All doctoral study programmes at Faculty of Medicine Comenius University, Bratislava | III | General Medicine and Dentistry |
Dissertation I and II, Dissertation exam. Defense of the dissertation. | Immunology | III | General Medicine |
Clinical Immunology | General Medicine | II | General Medicine |
V.2.a - Name of the study programme | V.2.b - Degree | V.2.c - Field of study |
---|---|---|
Immunology | II | General Medicine |
Immunology | II | Dentistry |
Clinical Immunology | II | General Medicine |
New Trends in Medical Microbiology and Immunology | III | All doctoral study programmes in Faculty of Medicine, Comenius University, Bratislava |
Dissertation I and II, Dissertation exam. Defense of the dissertation. | III | General Medicine |
Bucova, M; Lietava, J; (...); Petrek, M. Association of MCP-1-2518 A/G Single Nucleotide Polymorphism with the Serum Level of CRP in Slovak Patients with Ischemic Heart Disease, Angina Pectoris, and Hypertension. 2009 MEDIATORS OF INFLAMMATION 2009 IF=4,4, Q2
Bucova M., Suchankova M., Dzurilla M., Vrlik M., Novosadova H., Tedlova E., Urban S, Hornakova E., Seligova M., Durmanova V., Penz P., Javor J., Paulovicova E. Inflammatory Marker sTREM-1 Reflects the Clinical Stage and Respiratory Tract Obstruction in Allergic Asthma Bronchiale Patients and Correlates with Number of Neutrophils. Mediators Inflamm . 2012:2012:628754. doi: 10.1155/2012/628754. Epub 2012 Jul 5. Q2; IF=4,4
Kluckova K., Kozak J., Szaboova K., Rychly B., Svajdler M., Suchankova M., Tibenska E., Filova B., Steno J., Matejcik V., Homolova M., Bucova, M. TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients. Mediators of Inflammation; jul 1 2020; 2020. DOI10.1155/2020/1798147; Q2; IF= 4,6.
Suchankova M, Urban J, Ganovska M, Tibenska E, Szaboova K, Tedlova E, Sandor F, Majer I, Bobovcak M, Jonner I, Konig B, Bucova M. TREM-1 and TREM-2 Expression on CD14+ Cells in Bronchoalveolar Lavage Fluid in Pulmonary Sarcoidosis and Hypersensitivity Pneumonitis in the Context of T Cell Immune Response. Mediators Inflamm. 2020 May 14;2020:9501617. doi: 10.1155/2020/9501617. eCollection 2020. Q2; IF= 4,6.
Bucova M., Kluckova K., Kozak J., Rychly B., Suchankova M., Svajdler M., Matejcik V., Steno J., Zsemlye E., Durmanova V. HLA-G 14bp Ins/Del Polymorphism, Plasma Level of Soluble HLA-G, and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients. Diagnostics May 2022; Volume12; Issue5. DOI10.3390/diagnostics12051099. Q2, IF 3,6.
Durmanova, V., Mikolaskova, I., Zsemlye, E., Ocenasova, A., Bandzuchova, H., Suchankova, M., Kollarik, B., Palacka, P., Zvarik, M., Bucova, M., Hunakova, L. Association of HLA-G Expression, Its Genetic Variants and Related Neuro-Immunomodulation with Characteristics of Bladder Carcinoma. CANCERS Volume16 Issue22, DOI10.3390/cancers16223877, Q1. IF=4,5
Kluckova K., Kozak J., Szaboova K., Rychly B., Svajdler M., Suchankova M., Tibenska E., Filova B., Steno J., Matejcik V., Homolova M., Bucova, M. TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients. Mediators of Inflammation; jul 1 2020; 2020. DOI10.1155/2020/1798147; Q2; IF= 4,6.
Bucova M., Kluckova K., Kozak J., Rychly B., Suchankova M., Svajdler M., Matejcik V., Steno J., Zsemlye E., Durmanova V. HLA-G 14bp Ins/Del Polymorphism, Plasma Level of Soluble HLA-G, and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients. Diagnostics May 2022; Volume12; Issue5. DOI10.3390/diagnostics12051099. Q2, IF= 3,6.
Suchankova, M, Urban J, Ganovska M, Tibenska E, Szaboova K, Tedlova E, Sandor F, Majer I, Bobovcak M, Jonner I, Konig B, Bucova M. TREM-1 and TREM-2 Expression on CD14+ Cells in Bronchoalveolar Lavage Fluid in Pulmonary Sarcoidosis and Hypersensitivity Pneumonitis in the Context of T Cell Immune Response. Mediators Inflamm. 2020 May 14;2020:9501617. doi: 10.1155/2020/9501617. eCollection 2020. Q2; IF= 4,6.
Bucova M., Majernikova B., Durmanova V., Cudrakova D., Gmitterova K., Lisa I., Klimova E., Kluckova K., Buc M. HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis. Neurol Sci. 2020 Mar;41(3):599-604. doi: 10.1007/s10072-019-04136-3. Epub 2019 Nov 14. PMID: 31728855 Q2; IF= 3,3.
Bucova, M; Lietava, J; (...); Petrek, M. Association of MCP-1-2518 A/G Single Nucleotide Polymorphism with the Serum Level of CRP in Slovak Patients with Ischemic Heart Disease, Angina Pectoris, and Hypertension. 2009 MEDIATORS OF INFLAMMATION 2009 IF=4,4, Q2
Zopár citácií:
1. Wang, YY; Zhang, WL; (...); Hui, RT. Genetic variants of the monocyte chemoattractant protein-1 gene and its receptor CCR2 and risk of coronary artery disease: A meta-analysis. Nov 2011 ATHEROSCLEROSIS 219 (1) , pp.224-230IF=4,9; Q1
2. Dommel, S., Blüher, M.Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State? INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Vol 22, Issue 3 DOI10.3390/ijms22031500 IF=4,9; Q1
3. Dusi, V; Ghidoni, A; (...); Calvillo, L. Chemokines and Heart Disease: A Network Connecting Cardiovascular Biology to Immune and Autonomic Nervous Systems. 2016 MEDIATORS OF INFLAMMATION 2016. IF=4,4; Q2
4. Jing, YL; Zhu, DL; (...); Shen, SM. Monocyte chemoattractant protein 1-2518 A/G polymorphism and susceptibility to type 2 diabetes in a Chinese population. Feb 20 2011. CLINICA CHIMICA ACTA412 (5-6) , pp.466-469. IF=3,2; Q1/Q2
5. Amorim, FG; Campagnaro, BP; (...); Meyrelles, SS. Association of Interleukin-6 Gene Polymorphism With Angina Pectoris. Oct 2011 ANGIOLOGY 62 (7) , pp.549-553.IF=2,6; Q2
Bucova M., Suchankova M., Dzurilla M., Vrlik M., Novosadova H., Tedlova E., Urban S, Hornakova E., Seligova M., Durmanova V., Penz P., Javor J., Paulovicova E. Inflammatory Marker sTREM-1 Reflects the Clinical Stage and Respiratory Tract Obstruction in Allergic Asthma Bronchiale Patients and Correlates with Number of Neutrophils. Mediators Inflamm . 2012:2012:628754. doi: 10.1155/2012/628754. Epub 2012 Jul 5. Q2; IF=4,4
Zopár citácií:
1. Croteau-Chonka, DC; Qiu, WL; (...); Raby, BA. Gene Expression Profiling in Blood Provides Reproducible Molecular Insights into Asthma Control. AMERICAN JOURNAL of RESPIRATORY and CRITICAL CARE MEDICINE 2017 Jan 15;195(2):179-188. doi: 10.1164/rccm.201601-0107OC.Jan 15 2017; 195 (2) , pp.179-188. Q1, IF= 24,7
2.Sánchez-Ovando, S., Simpson, J.L., Barker, D., Baines, K.J., Wark, P.A.B. Transcriptomics of biopsies identifies novel genes and pathways linked to neutrophilic inflammation in severe asthma. 2021 Clinical and Experimental Allergy 51(10), pp. 1279-1294. Q1; IF=6,3.
3.Whole blood transcriptional variations between responders and non-responders in asthma patients receiving omalizumab Upchurch, K., Wiest, M., Cardenas, J., (...), Turner, J., Oh, S. 2020 Clinical and Experimental Allergy 50(9), pp. 1017-1034. Q1, IF=6,3.
4.de Oliveira Matos, A., dos Santos Dantas, P.H., Figueira Marques Silva-Sales, M., Sales-Campos, H. The role of the triggering receptor expressed on myeloid cells-1 (TREM-1) in non-bacterial infections 2020 Critical Reviews in Microbiology 46(3), pp. 237-252. Q1; IF=6
5.Karagianni, A.E., Kurian, D., Cillán-Garcia, E., (...), Wishart, T.M., Pirie, R.S. Training associated alterations in equine respiratory immunity using a multiomics comparative approach 2022 Scientific Reports 12(1),427. Q1, IF=3,8
Kluckova K., Kozak J., Szaboova K., Rychly B., Svajdler M., Suchankova M., Tibenska E., Filova B., Steno J., Matejcik V., Homolova M., Bucova, M. TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients. Mediators of Inflammation; jul 1 2020; 2020. DOI10.1155/2020/1798147; Q2; IF= 4,6
Zopár citácií:
1. Sun, R; Han, RW; (...); Kim, AH. TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma. SCIENCE ADVANCES 2023 May 12;9(19):eade3559. doi: 10.1126/sciadv.ade3559. Epub 2023 May 12. Q1, IF (2022)= 13,6
2. Shen, P; Zhang, TY; (...); Duan, YN. Recombinant P40 protein of Schistosoma japonicum inhibits TREM-1 expression in RAW264.7 cells via FOXO3a May 2022. BIOMED PHARMACOTHER. 2022 May:149:112826. doi: 10.1016/j.biopha.2022.112826. Epub 2022 Mar 17. Q1, IF= 7,5
3. Cheng, X; Wang, XW; (...); Peng, WJ. Systematic Pan-Cancer Analysis Identifies. TREM2 as an Immunological and Prognostic Biomarker. FRONTIERS IN IMMUNOLOGY. Front Immunol. 2021 Feb 17:12:646523. doi: 10.3389/fimmu.2021.646523. eCollection 2021. Q1. IF= 7,3
4. Singh, H; Rai, V; (...); Agrawal, DK. Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates. EXPERT OPINION ON THERAPEUTIC PATENTS. 2021 Jun;31(6):549-561. doi: 10.1080/13543776.2021.1883587. Epub 2021 Feb 8. Q1, IF=6,6
5. Cao, YH; Wang, YW; (...); Fu, C. The ratio of urinary TREM-1/TREM-2 mRNA expression in chronic kidney disease and renal fibrosis. Jan 1 2021 ANNALS OF MEDICINE 53 (1) , pp.1010-1018; IF=4,9; Q1
Bucova M., Majernikova B., Durmanova V., Cudrakova D., Gmitterova K., Lisa I., Klimova E., Kluckova K., Buc M. HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis. Neurol Sci. 2020 Mar;41(3):599-604. doi: 10.1007/s10072-019-04136-3. Epub 2019 Nov 14. PMID: 31728855 Q2; IF= 3,3
Zopár citácií:
1. Mo, JL; Hu, J and Cheng, XL. The role of high mobility group box 1 in neuroinflammatory related diseases. BIOMEDICINE & PHARMACOTHERAPY. 2023 May:161:114541. doi: 10.1016/j.biopha.2023.114541. Q1, IF= 7,5
2.Duarte, LF; Villalobos, V; (...); Gonzalez, PA. Asymptomatic herpes simplex virus brain infection elicits cellular senescence phenotypes in the central nervous system of mice suffering multiple sclerosis-like disease. Jul 4 2024 COMMUNICATIONS BIOLOGY 7 (1). IF=5,2; Q1
3.Mills, J; Ladner, L; (...); Theus, MH. Cross-Talk and Subset Control of Microglia and Associated Myeloid Cells in Neurological Disorders. Nov 2022, CELLS, 2022 Oct 25;11(21):3364. doi: 10.3390/cells11213364.Q2, IF= 6,6
4. Safavynia, SA; Goldstein, PA and Evered, LA. Mitigation of perioperative neurocognitive disorders: A holistic approach. FRONTIERS IN AGING NEUROSCIENCE, 2022 Jul 27:14:949148. doi: 10.3389/fnagi.2022.949148 Q1, 5,3.
5.Ikram, FZ; Arulsamy, A; (...); Shaikh, MF. The Role of High Mobility Group Box 1 (HMGB1) in Neurodegeneration: A Systematic Review 2022 CURRENT NEUROPHARMACOLOGY 20 (11) , pp.2221-2245. Q1, IF=4,8
6.Mo, JL; Hu, J and Cheng, XL. The role of high mobility group box 1 in neuroinflammatory related diseases. BIOMEDICINE & PHARMACOTHERAPY. 2023 May:161:114541. doi: 10.1016/j.biopha.2023.114541. Q1, IF= 6,9.
7. Mohammad, G and Kowluru, RA. Involvement of High Mobility Group Box I Protein in Optic Nerve Damage in Diabetes. 2022EYE AND BRAIN 14 , pp.59-69. Q1, IF=3,1
Urban J., Suchankova M., Ganovska M., Leksa V., Sandor F., Tedlova E., Konig, B, Bucova, M. The role of CX3CL1 and Adam17 in pathogenesis of diffuse parenchymal lung diseases. Diagnostics Vol 11, Issue 2021 Article number 1074 IF=3, 9; Q1
Zopár citácií:
1. Schwartz, J., Capistrano, K.J., Gluck, J., Hezarkhani, A., Naqvi, A.R. SARS-CoV-2, periodontal pathogens, and host factors: The trinity of oral post-acute sequelae of COVID-19. Reviews in Medical Virology 2024, 34(3),e2543 IF=9; Q1
2. Akdeniz, Y.S., Özkan, S. New markers in chronic obstructive pulmonary disease 2024. Advances in Clinical Chemistry 123, pp. 1-63 IF=9; Q1
3. Alarcón-Sánchez, M.A., Becerra-Ruiz, J.S., Guerrero-Velázquez, C., Mosaddad, S.A., Heboyan, A. The role of the CX3CL1/CX3CR1 axis as potential inflammatory biomarkers in subjects with periodontitis and rheumatoid arthritis: A systematic review. 2024 Immunity, Inflammation and Disease. 12(2),e1181 IF=3,1; Q3
4. Hu, H., Yang, H., Liu, Y., Yan, B. Pathogenesis of Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis: A Concise Review With an Emphasis on Type I Interferon System 2022. Frontiers in Medicine. 8,833114 IF=3,1; Q1
VEGA 1/0426/24 - Molecular mechanisms of fibrotic and inflammatory processes of diffuse parenchymal lung diseases - analyzes of defined markers in bronchoalveolar lavages and their significance in clinical practice
2024 - 2027
Project representative
Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences
VEGA 1/0758/20 - Diffuse parenchymal lung diseases - inflammation, immunological mechanisms and determination of novel markers for diagnosis and differential diagnosis
2020 - 2022
Project leader
Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences
VEGA 1/0212/17: TREM-1, TREM-2 tests as new diagnostic and differential-diagnostic tests for sarcoidosis and other diffuse parenchymal lung diseases. Attempt at immunological classification of pulmonary diseases.
2017 - 2019
Project leader
Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences.
APVV-22-0231 - Therapeutic potential of stress-reducing intervention in complex cancer care.
2023 - 2027
Coauthor
Slovak Research and Development Agency
„APVV-21-0197: Investigation of the impact of stress on the course of cancer (project leader: Božena Smolková, MSc., PhD.)
2022-2026
Coauthor
Slovak Research and Development Agency
VII.a - Activity, position | VII.b - Name of the institution, board | VII.c - Duration |
---|---|---|
The main organizer of the first days of young Czechoslovak immunologists under the age of 35 in Tatranská Lomnica | Slovak Immunologic Society | october 1988 |
Organizer of regular monthly seminars of the Slovak Immunological Society and the Society of Slovak Allergiologists and Immunologists | Slovak Immunologic Society (SIS) | roky 1995 - 2000 |
Member of the Committee of the Slovak Immunological Society | Slovak Immunologic Society (SIS) | 2012- up to now |
Member of the working group of the Czech and Slovak forum for sepsis and MODS | Czech and Slovak forum for sepsis and MODS in Ostrava, Czech republic | 2003 - 2014 |
VIII.a - Name of the institution | VIII.b - Address of the institution | VIII.c - Duration (indicate the duration of stay) | VIII.d - Mobility scheme, employment contract, other (describe) |
---|---|---|---|
Department of Immunology, Faculty of Medicine, Palacky University Olomouc | Faculty of Medicine, Palacky University, Olomouc, Czech Republic | 5 - times one week study stay during years 2005, 2006, 2007, 2008, 2009 | Under the leadership of prof. Dr. Martin Petřek, CSc., and assoc. prof. Dr. František Mrázek, PhD.) |
Department of Immunology, Faculty of Medicine, Palacky University Olomouc; and Institute of Immunogenetics and Immunogenomics | Faculty of Medicine, Palacky University, Olomouc, Czech Republic | 2009 - up to now; Repeated participation in PhD and assoc. prof. defenses as opponent of theses | Dean office of Faculty of Medicine, Palacky University, Olomouc, Czech Republic |
Co-authore four university scripts and four textbooks.
Certification in Medical Microbiology, obtained in the year 1989.
Awards for publications:
1., Awarding the work of Bucova M., Suchankova M., et al. (Mediators of Inflammation, 2012) from "Word Biomedical Frontiers" for an innovative approach and potential significant impact in diagnostics and therapy
2., Appreciation of the work of the authors Suchankova M., Bucova M, et al. (Respirology, 2013) for the innovative approach and special interest of the drug development sector ("Global Medical Discovery").
3., The Literary Fund awarded the "Premium for scientific and professional literature for the year 2006" for the book: Kresánek, Furková K. et al. (Bucová M. - co-author) Adolescent medicine. Martin, Osveta 2006, 375 p.
4th, 2nd place for an original publication in the journal Cardiology in 2005 (work: Pecháň I, Bucová M, Daňová K et al. Cytokine levels in patients before and after closure of an atrial septal defect (type II) with an Amplatz occluder. Cardiol 2005; 14(6):313-318.
1. Student management within ŠVOČ ( student scientific activity) - Terézia Pinčíková - in 2005 - 1st place in the paraclinical section at ŠVOČ at Faculty of Medicine Comenius University in Bratislava.
2. Leading students within the PhD conference - 2 times 2nd place at the PhD conference in Bratislava (2011 and 2013). (doctoral student Magda Suchánková, MD)
3. Leading students within the PhD conference - r. 2018 – doctoral student, 3rd place in the faculty round of the PhD conference (Maruščáková L.)
4. Leading students within the PhD conference - 2 times 2nd place at the PhD conference in Bratislava (years 2019, 2021); (doctoral student: MUDr. Ján Urban)
5. Leading students within the PhD conference - 2019: 2nd place at the PhD conference in Bratislava (doctoral student Kristína Klučková, MD)
6. Leading doctoral student : year 2019 - first place (Urban Ján) in Olomouc at the 21st Congress of the Czech and Slovak Pneumological and Physiological Society